Untangling the Origin and Function of Granulovacuolar Degeneration Bodies in Neurodegenerative Proteinopathies

Overview

Journal Acta Neuropathol Commun

Publisher Biomed Central

Specialty Neurology

Date 2020 Sep 5

PMID 32883341

Citations 9

Authors

Vera I Wiersma

Jeroen J M Hoozemans

Wiep Scheper

Affiliations

Soon will be listed here.

Abstract

In the brains of tauopathy patients, tau pathology coincides with the presence of granulovacuolar degeneration bodies (GVBs) both at the regional and cellular level. Recently, it was shown that intracellular tau pathology causes GVB formation in experimental models thus explaining the strong correlation between these neuropathological hallmarks in the human brain. These novel models of GVB formation provide opportunities for future research into GVB biology, but also urge reevaluation of previous post-mortem observations. Here, we review neuropathological data on GVBs in tauopathies and other neurodegenerative proteinopathies. We discuss the possibility that intracellular aggregates composed of proteins other than tau are also able to induce GVB formation. Furthermore, the potential mechanisms of GVB formation and the downstream functional implications hereof are outlined in view of the current available data. In addition, we provide guidelines for the identification of GVBs in tissue and cell models that will help to facilitate and streamline research towards the elucidation of the role of these enigmatic and understudied structures in neurodegeneration.

Citing Articles

Retinal ganglion cell vulnerability to pathogenic tau in Alzheimer's disease.

Davis M, Robinson E, Koronyo Y, Salobrar-Garcia E, Rentsendorj A, Gaire B Acta Neuropathol Commun. 2025; 13(1):31.

PMID: 39955563 PMC: 11829413. DOI: 10.1186/s40478-025-01935-y.

The necroptosis cell death pathway drives neurodegeneration in Alzheimer's disease.

Balusu S, De Strooper B Acta Neuropathol. 2024; 147(1):96.

PMID: 38852117 PMC: 11162975. DOI: 10.1007/s00401-024-02747-5.

Structurally and Morphologically Distinct Pathological Tau Assemblies Differentially Affect GVB Accumulation.

Jorge-Oliva M, van Weering J, Scheper W Int J Mol Sci. 2023; 24(13).

PMID: 37446051 PMC: 10341458. DOI: 10.3390/ijms241310865.

Neuropathology of the Alzheimer's continuum: an update.

Jellinger K Free Neuropathol. 2023; 1.

PMID: 37283686 PMC: 10209886. DOI: 10.17879/freeneuropathology-2020-3050.

Extracellular Vesicles, Cell-Penetrating Peptides and miRNAs as Future Novel Therapeutic Interventions for Parkinson's and Alzheimer's Disease.

Keighron C, Avazzadeh S, Goljanek-Whysall K, McDonagh B, Howard L, Ritter T Biomedicines. 2023; 11(3).

PMID: 36979707 PMC: 10045119. DOI: 10.3390/biomedicines11030728.

References

Braak H, Del Tredici K, Rub U, de Vos R, Jansen Steur E, Braak E . Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2002; 24(2):197-211. DOI: 10.1016/s0197-4580(02)00065-9. View

Calafate S, Flavin W, Verstreken P, Moechars D . Loss of Bin1 Promotes the Propagation of Tau Pathology. Cell Rep. 2016; 17(4):931-940. DOI: 10.1016/j.celrep.2016.09.063. View

Poorkaj P, Bird T, Wijsman E, Nemens E, Garruto R, Anderson L . Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998; 43(6):815-25. DOI: 10.1002/ana.410430617. View

Eidelberg D, Sotrel A, Joachim C, Selkoe D, Forman A, Pendlebury W . Adult onset Hallervorden-Spatz disease with neurofibrillary pathology. A discrete clinicopathological entity. Brain. 1987; 110 ( Pt 4):993-1013. DOI: 10.1093/brain/110.4.993. View

Yokota O, Terada S, Ishizu H, Tsuchiya K, Kitamura Y, Ikeda K . NACP/alpha-synuclein immunoreactivity in diffuse neurofibrillary tangles with calcification (DNTC). Acta Neuropathol. 2002; 104(4):333-41. DOI: 10.1007/s00401-002-0545-5. View

Suzuki K, Parker C, Pentchev P, Katz D, Ghetti B, DAGOSTINO A . Neurofibrillary tangles in Niemann-Pick disease type C. Acta Neuropathol. 1995; 89(3):227-38. DOI: 10.1007/BF00309338. View

Ikegami K, Kimura T, Katsuragi S, Ono T, Yamamoto H, Miyamoto E . Immunohistochemical examination of phosphorylated tau in granulovacuolar degeneration granules. Psychiatry Clin Neurosci. 1996; 50(3):137-40. DOI: 10.1111/j.1440-1819.1996.tb01678.x. View

Stadelmann C, Deckwerth T, Srinivasan A, Bancher C, Bruck W, Jellinger K . Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am J Pathol. 1999; 155(5):1459-66. PMC: 1866960. DOI: 10.1016/S0002-9440(10)65460-0. View

Kohler C . Granulovacuolar degeneration: a neurodegenerative change that accompanies tau pathology. Acta Neuropathol. 2016; 132(3):339-59. DOI: 10.1007/s00401-016-1562-0. View

10.

Arima K, Mizutani T, Alim M, Izumiyama Y, Hirai S, Ueda K . NACP/alpha-synuclein and tau constitute two distinctive subsets of filaments in the same neuronal inclusions in brains from a family of parkinsonism and dementia with Lewy bodies: double-immunolabeling fluorescence and electron microscopic studies. Acta Neuropathol. 2000; 100(2):115-21. DOI: 10.1007/s004010050002. View

11.

Yan T, Wang L, Gao J, Siedlak S, Huntley M, Termsarasab P . Rab10 Phosphorylation is a Prominent Pathological Feature in Alzheimer's Disease. J Alzheimers Dis. 2018; 63(1):157-165. PMC: 6008156. DOI: 10.3233/JAD-180023. View

12.

Hoozemans J, van Haastert E, Eikelenboom P, de Vos R, Rozemuller J, Scheper W . Activation of the unfolded protein response in Parkinson's disease. Biochem Biophys Res Commun. 2007; 354(3):707-11. DOI: 10.1016/j.bbrc.2007.01.043. View

13.

Heath J, Siedlak S, Zhu X, Lee H, Thakur A, Yan R . Widespread distribution of reticulon-3 in various neurodegenerative diseases. Neuropathology. 2010; 30(6):574-9. PMC: 2902651. DOI: 10.1111/j.1440-1789.2010.01107.x. View

14.

van Weering J, Scheper W . Endolysosome and Autolysosome Dysfunction in Alzheimer's Disease: Where Intracellular and Extracellular Meet. CNS Drugs. 2019; 33(7):639-648. PMC: 6647502. DOI: 10.1007/s40263-019-00643-1. View

15.

Zhu X, Rottkamp C, Boux H, Takeda A, Perry G, Smith M . Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell cycle-related events in Alzheimer disease. J Neuropathol Exp Neurol. 2000; 59(10):880-8. DOI: 10.1093/jnen/59.10.880. View

16.

Kohler C, Dinekov M, Gotz J . Granulovacuolar degeneration and unfolded protein response in mouse models of tauopathy and Aβ amyloidosis. Neurobiol Dis. 2014; 71:169-79. DOI: 10.1016/j.nbd.2014.07.006. View

17.

Nelson P, Alafuzoff I, Bigio E, Bouras C, Braak H, Cairns N . Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol. 2012; 71(5):362-81. PMC: 3560290. DOI: 10.1097/NEN.0b013e31825018f7. View

18.

Gomez-Isla T, HOLLISTER R, West H, Mui S, Growdon J, Petersen R . Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997; 41(1):17-24. DOI: 10.1002/ana.410410106. View

19.

Burger P, Vogel F . The development of the pathologic changes of Alzheimer's disease and senile dementia in patients with Down's syndrome. Am J Pathol. 1973; 73(2):457-76. PMC: 1904076. View

20.

Polito V, Li H, Martini-Stoica H, Wang B, Yang L, Xu Y . Selective clearance of aberrant tau proteins and rescue of neurotoxicity by transcription factor EB. EMBO Mol Med. 2014; 6(9):1142-60. PMC: 4197862. DOI: 10.15252/emmm.201303671. View